The use of peptide aptamers such as the chimeric decoy protein (GFP-KA2) to target the mutant p53-DAB2IP complex has been shown to significantly reduce inflammation-driven and insulin-driven invasion in vitro and xenograft growth and spread in breast cancer models in vivo155. Here, TP53 is linked to breast carcinoma.